Summary of Version 3 Criteria Changes

The Criteria for clinical use of immunoglobulin in Australia (Criteria) is under a continuous review cycle. The table below summarises changes made by medical condition and indication. This table will be updated when any change is made.

                                                            Neurology Medical Conditions

Medical Condition Indication/s Summary of Changes Version number

Chronic inflammatory demyelinating polyneuropathy (CIDP), (including IgG and IgA paraproteinaemic demyelinating neuropathies)

  • Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) for patients in whom walking is compromised or there is significant disability
  • Relapse of chronic inflammatory demyelinating polyneuropathy (CIDP) patients within six months of commencement of trial off Ig therapy
  • Correction to bibliography links.
  • Minor changes to the assessor instructions.
  • Correction of data entry error.
  • Subcutaneous administration of Ig can be considered as an alternative to intravenous Ig (IVIg) following stabilisation with IVIg.